Received Feb 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
Adult-onset Still's disease; Vaccine type: mRNA (Pfizer); COVID-19 infection; Vaccine type: mRNA (Pfizer); COVID-19 infection; This is a literature report for the following literature source(s). A patient (age and gender not provided) received BNT162b2 (BNT162B2 NOS), as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: STILL'S DISEASE (hospitalization, medically significant), 8 days after the suspect product(s) administration, outcome "recovered", described as "Adult-onset Still's disease"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Vaccine type: mRNA (Pfizer); COVID-19 infection". The patient underwent the following laboratory tests and procedures: Serum ferritin: 6500 ng/ml. Therapeutic measures were taken as a result of still's disease, drug ineffective, covid-19. Clinical course: Vaccine type: mRNA (Pfizer), Onset (Day/s): 8, Fever: True, Arthritis: True, Rash: False, Ferritin level (ng/mL): 6500, Hospitalized: True, Treatment: Steroids + IVIG. This systematic review synthesises the clinical characteristics of 13 published case reports describing new onset or flare episodes of AOSD occurring temporally after COVID-19 vaccination. The reported cases demonstrated typical AOSD features, including high fever, arthritis or arthralgia, elevated inflammatory markers, and the classic salmon-coloured rash in some instances. These findings provide a descriptive overview of published observations and should not be interpreted as evidence of incidence, increased risk, or causality. Because all available evidence derives from isolated case reports without control groups, it is not possible to determine whether vaccination influences AOSD flare rates beyond background disease variability or whether the temporal associations described are coincidental. The small number of cases and potential publication bias further limit generalisability. Nonetheless, clinicians should remain attentive when evaluating febrile or inflammatory symptoms in recently vaccinated individuals with autoinflammatory conditions. All patients recovered with timely corticosteroid therapy, with some requiring biologic agents. Future research using pharmacovigilance databases, prospective registries, and studies including unvaccinated comparator groups is necessary to clarify potential risk factors, explore underlying mechanisms, and guide recommendations for revaccination in individuals with prior AOSD flares.; Sender's Comments: Vaccine efficacy varies from person to person and is affected by many factors. The association between the event drug ineffective (COVID-19) with the suspect product BNT162B2 cannot be fully excluded. The event Still's disease is conservatively assessed as related to the suspect drug based on plausible temporal association but consider also possible contributory effects from medical history of the patient and/or concomitant medications. The impact of this report on the benefit-risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, ethics committees and investigators, as appropriate.
Test Name: Ferritin Level; Result Unstructured Data: Test Result:6500 ng/ml